WindMIL Therapeutics
PrivateLast Round
Series B
Jun 18, 2018
Total Funding Raised
$43.5M
Company Overview
WindMIL Therapeutics is a biotechnology company that develops autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
WindMIL Therapeutics Comparables
Compare WindMIL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Triumvira Immunologics | 81% | |
| Marker Therapeutics Inc | 77% | |
| Rapa Therapeutics | 76% | |
WindMIL Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 18, 2018 | ||||
| Series A | Mar 24, 2016 |
WindMIL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foxkiser | Series B, Series A |
| Domain Associates | Series B, Series A |
| Kintegral Asset Management | Series B |
| Qiming | Series B |
| Forward Equity Partners | Series B |
WindMIL Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about WindMIL Therapeutics's valuation, stock price, and market status.